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Abstract
Purpose. A preliminary investigation was conducted to evaluate and compare the effectiveness of two closed-system
products in preventing contamination of typical pharmacy workplace surfaces with cyclophosphamide during simulated
hazardous drug preparation activities in a controlled laboratory setting.
Methods. Two separate trials simulating hazardous drug compounding using cyclophosphamide were performed with
two different closed-system products. Prior to each trial, work area surfaces of the biological safety cabinet (BSC)
workbench, the BSC airfoil and front grill, and the floor below the BSC were cleaned, and wipe samples were col-
lected and analyzed to determine, if present, levels of cyclophosphamide. Following each trial, wipe samples were
collected from the work area surfaces to determine the hazardous drug containment effectiveness of each closed-
system product.
Results. Cyclophosphamide was not detected on work area surfaces prior to each trial. Low levels were detected on
the BSC workbench surface following both trials.
Discussion. Based on the limited number of samples obtained during this preliminary study and the determination of
the presence of the chemical of interest on the drug vials, no statistical evaluation was performed to compare the relative
effectiveness of the two systems tested. Work practices and procedures regarding product operation may affect haz-
ardous drug containment and worker safety. Further study and statistical analyses are needed.
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Introduction
Worldwide, cancer is the leading cause of death with an
estimated 7.9 million deaths in 2007.
1 These numbers
are expected to double before 2030.
1 Given the increase
in the number of patients, the increasing numbers of
new agents being developed to treat cancer and the
increasing complexity of chemotherapy combination
therapy, there will be a dramatic increase in the
number of healthcare workers exposed to hazardous
drugs from the current estimate of 5.5 million workers
per year.
2
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since the 1970s as a potential health hazard to workers.
In the early 1990s, the American Society of Health-
System Pharmacists was the ﬁrst organization to for-
mally deﬁne ‘hazardous drugs’.
3 Drugs are classiﬁed as
hazardous if studies in animals or humans indicate that
exposures to them have a potential for causing cancer,
developmental or reproductive toxicity, or harm to
organs.
3 Both the Occupational Safety and Health
Administration and the National Institute for
Occupational Safety and Health (NIOSH) have adopted
the aforementioned deﬁnition.
4,5 NIOSH expands the
deﬁnition to consider a drug hazardous if it exhibits
one or more of the following six characteristics:
1. Carcinogenicity;
2. teratogenicity;
3. reproductive toxicity;
4. organ toxicity at low doses;
5. genotoxicity; and
6. structure and toxicity proﬁles of new drugs that
mimic existing drugs determined hazardous by the
above criteria.
NIOSH and The United States Pharmacopeia’s
General Chapter 797 (USP 797) recommend using a
closed-system transfer device to minimize occupational
exposures to antineoplastic and other hazardous
drugs.
5,6 The NIOSH deﬁnition of a closed system is
one that mechanically prevents the transfer of environ-
mental contaminants into the system and the escape of
drug or vapor out of the system. Some studies have
shown the beneﬁts of a closed system in reducing hazard-
ous drug surface contamination when compared to tra-
ditional preparation techniques in the clinical setting.
7–9
This study was conducted to evaluate and compare
two closed-system products during simulated hazard-
ous drug preparation activities using a known amount
of cyclophosphamide in a laboratory setting. Attempts
were made to control, minimize, and evaluate other
known sources of environmental contamination which
may be found in clinical settings to help focus on the
closed-system products’ eﬃciencies in minimizing con-
tamination of typical pharmacy workplace surfaces.
Methods
The study site was an experimental laboratory setting.
A Class 100 clean room and a Class II Biological Safety
Cabinet (BSC) vented to the outdoors were utilized.
There was no knowledge of prior use or handling of
cyclophosphamide in the clean room or BSC at the
study site.
Two closed-system products which appeared to be
commonly used in health care settings were evaluated.
Both products include vial and intravenous (IV)
bag adaptors and connectors that were designed to
prevent hazardous drug release. The ﬁrst was
ChemoCLAVE
TM Oncology Preparation and
Delivery System (ICU Medical, Inc.) which include
the Genie
TM Closed Vial Access Device (REF CH-77),
the Spiros
TM Closed Male Connector (REF CH2000);
(Figure 1), and the Access Device, IV Bag, Clave
Connector (REF CH-10). Once the Spiros was attached
to a syringe and the Genie was attached to a vial, three
user steps were required for ﬂuid transfer. The needle-
free Spiros was connected to the Genie Closed Vial
Access Device by inserting the male end of the Spiros
into the female end of the Genie, pressing, and twisting.
Disconnection required twisting in the opposite direc-
tion and withdrawing from the Genie. Access to the IV
Access Device was identical.
The second product was PhaSeal (Carmel Pharma),
which included the Protector
TM vial access device (REF
P50), the Injector
TM Luer Lock male connector (REF
N31); Figure 2), and the Infusion Adaptor (REF
C100). Once the Injector Luer Lock was attached to a
Figure 1. ChemoCLAVE
TM System: Genie Closed Vial Access
Device with internal balloon and Spiros Closed Male Connector.
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user steps were required for ﬂuid transfer. The Injector,
with a contained needle, was connected to the Protector
by inserting the male end of the Injector into the female
end of the Protector, pressing, twisting, lifting a lever
on the Injector (to release a needle cap), and pushing
the needle into the vial. Disconnection was achieved by
pulling the needle out of the vial, twisting in the oppo-
site direction, and withdrawing from the Protector.
Access to the Infusion Adaptor was identical.
A certiﬁed pharmacy technician specializing in
oncology preparations performed all simulated com-
pounding duties using standard aseptic and hazardous
drug preparation techniques and personal protective
equipment. The technician had approximately 1 year
experience working with ChemoCLAVE and approxi-
mately 7 years experience working with PhaSeal.
Cyclophosphamide was selected as a hazardous drug
marker for its common use in the clinical setting and
the availability of a sensitive analytical method to
detect trace levels of the chemical. The analytical limit
of detection for cyclophosphamide was 15.7ng per
sample. Wipe samples were collected from strategic
locations and items to sample for cyclophosphamide
on surfaces. All wipe samples were collected using
Cyto Wipe Kits (Exposure Control B.V.).
At each sampling location(s), the surfaces were mea-
sured to determine the surface area that was to be sam-
pled. A new pair of nitrile gloves was donned prior to
the collection of each sample. Using a medicine drop-
per,  17ml of solution was applied to each surface. A
paper tissue was used to spread the solution over the
entire pre-measured area and the area was sampled by
wiping in multiple directions using moderate hand pres-
sure. During the sampling, emphasis was placed on
sampling the surfaces in a manner as to not wipe out-
side of the measured surface area and to not damage
the tissue. The tissue was placed in a plastic 175-ml
sample bottle. A second tissue was used to completely
dry the surface using unidirectional wiping techniques
and was also placed in the same sample bottle.
For items that would not permit the solution to be
placed on the surface, approximately one-half of the
solution from the medicine dropper was placed directly
on the ﬁrst paper tissue. The surfaces were sampled at
each location as described above, the remaining solution
was placed on the second paper tissue, and the surface
was wiped a second time as described above, carefully
folding the tissue and completely drying the surface.
The study was performed over a 2-day period. On
Day 1 of the study, the site was prepared by measuring
and demarcating the surfaces to be sampled on the BSC
workbench (4400cm
2), the BSC airfoil and front grill
(2000cm
2), and the ﬂoor directly below and in front of
the BSC (4400cm
2). All of the surfaces that were selected
to be sampled were cleaned using Surface Safe
(Hospira). Surface Safe is a product that was designed
to inactivate cytotoxic drug substances including cyclo-
phosphamide, and remove them from surfaces using a
two-step application process. Following Surface Safe
application, the surfaces were further cleaned using ﬁl-
tered water and lint-free towels and allowed to dry.
In a separate area of the clean room, 40 vials con-
taining 1g of lyophilized cyclophosphamide powder
(Baxter) were removed from their individual outer
cardboard box packaging materials and randomly
divided into two groups of 20 vials each designated as
Vial Group 1 and Vial Group 2. Composite wipe sam-
ples were collected from the exterior surfaces of the
vials to determine if contamination was present on
the containers in their as-received conditions from the
manufacturer. All vials used during the study were sam-
pled. Five vials were wiped for each composite wipe
sample. The wipes were folded after each vial was
Figure 2. PhaSeal Protector 50 vial access device with
external balloon and Injector Luer Lock male connector.
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between vials during sampling.
On Day 2 of the study, the product trials were con-
ducted. The ChemoCLAVE trial was conducted ﬁrst
using Vial Group 1, followed by the PhaSeal trial
using Vial Group 2. Prior to each trial and after cleaning
with Surface Safe, a wipe sample was collected from the
demarcated surface areas of the BSC workbench, BSC
airfoil/grill, and the ﬂoor to determine if the surfaces
were free from cyclophosphamide contamination.
Vials were placed on protective/absorbent pads on
either side of the demarcated area within the BSC to
minimize possible exterior vial contamination from
contacting the sampling surfaces. For each trial, the
pharmacy technician donned a new pair of gloves and
performed compounding activities inside the BSC over
the demarcated areas. Each of the 20 cyclophospha-
mide vials were reconstituted using 50ml of 0.9%
sodium chloride for injection, then three individual vol-
umes of 5ml each were removed from each of the 20
vials and transferred to 10 IV bags (six transfers to each
bag) containing closed-system connectors (totals for
each trial: 60 transfers; 300ml solution; 6g cyclophos-
phamide.) The pharmacy technician was observed while
performing duties during the trials. The duration of
each trial was  1h. Following each trial, wipe samples
were collected from the demarcated areas of the BSC
workbench, BSC airfoil/grill, and the ﬂoor, and from
the pharmacy technician’s gloves. A composite sample
of both gloves used during the trial was collected uti-
lizing one tissue media for each glove. All exterior sur-
faces of the gloves were wiped. Concentrations were
reported in ng cyclophosphamide per cm
2 of surface
area, or for gloves, reported as total ng cyclophospha-
mide per pair.
A total of ﬁve ﬁeld blank samples were collected
during the study for quality control purposes. The
ﬁeld blank samples were handled similarly to environ-
mental wipe samples, only no surfaces were wiped.
Approximately one-half of the solution was placed on
each tissue media, and the tissues were folded and
placed in the sample bottles.
All of the wipe samples obtained were contained in
sample bottles as soon as possible after collection and
were stored in an insulated container with dry ice. At
the completion of the study, all samples were packaged
with dry ice and shipped to Exposure Control in The
Netherlands for analysis.
The wipe samples were prepared by adding 140ml of
a 0.03M NaOH solution. After extraction, a part of the
extract was subjected to laboratory ‘clean up’ opera-
tions.
10,11 Samples were analyzed using a gas chromato-
graph that was equipped with dual mass spectrometers
(GC-MSMS), which is an enhancement to the original
method developed for GC-MS.
12 Speciﬁcity and
sensitivity are increased using GC-MSMS in place of
GC-MS.
13
Results
Vial wipe sampling results
Cyclophosphamide was detected on the exterior of
some vials in Vial Group 1 (used for the
ChemoCLAVE trial.) Of the four composite wipe sam-
ples collected from Vial Group 1, two samples showed
detectable levels and two samples showed no cyclo-
phosphamide contamination. No cyclophosphamide
was detected on the exterior of vials intended for the
PhaSeal trial (Vial Group 2). Table 1 summarizes the
composite vial sample results.
Pre-trial wipe sampling results
No cyclophosphamide was detected on the BSC or
ﬂoor surfaces following cleaning with Surface Safe
and prior to both trials. Table 2 summarizes the pre-
trial sample results.
Post-trial wipe sampling results
Following the ChemoCLAVE
TM trial, no cyclophos-
phamide was detected on the BSC airfoil/grill or the
ﬂoor. Cyclophosphamide was detected on the BSC
workbench and the pharmacy technician’s pair of
gloves. Following the PhaSeal trial, cyclophospha-
mide was detected on the BSC workbench, but not on
the BSC airfoil/grill, the ﬂoor, or the pharmacy techni-
cian’s gloves. Table 3 summarizes the post-trial
sample results.
Quality control sample results
No cyclophosphamide was detected on the ﬁeld blank
samples.
Table 1. Summary of vial sample results
Vial group
Composite
samples
a
Cyclophosphamide
(ng)
1
(Used for ChemoCLAVE
TM
trial)
Sample 1
Sample 2
Sample 3
Sample 4
nd
b
nd
2694
17
2
(Used for PhaSeal trial)
Sample 1
Sample 2
Sample 3
Sample 4
nd
nd
nd
nd
aEach composite sample was taken from five 1g vials.
bnd¼not detected (cyclophosphamide<15.7ng).
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Surface contamination in pharmacies and treatment
areas has been a major concern. BSCs, countertops,
ﬂoors in and adjacent to preparation areas, tabletops,
chairs, and ﬂoors in treatment areas may have contami-
nation with hazardous drugs when a closed-system is not
used. A study examining the contamination in six sites in
the US and Canada found that measurable amounts of
the antineoplastic agents (cyclophosphamide, ifosfamide,
ﬂuorouracil) were detected in 75% of pharmacy samples
and 65% of administration samples.
14
Many factors may contribute to surface contamina-
tion in the clinical setting. Some studies have also shown
contamination on the exterior of vials as received from
manufacturers.
15,16 Unreported or inadequately cleaned
spills, transport and placement of contaminated objects,
patient body ﬂuids, and spreading by hand or foot con-
tact may contribute to surface contamination.
This study was conducted in a controlled laboratory
setting, using known amounts of cyclophosphamide,
while taking measures to minimize other known sources
of surface levels common in the clinical setting. This
approach was used to help focus on the closed-system
products’ eﬃciencies in minimizing contamination of
typical pharmacy workplace surfaces.
The results from the analyses of the wipe samples
collected from the BSC workbench, airfoil/grill, and
the ﬂoor following cleaning with Surface Safe
showed that the surfaces were free from detectable
levels of cyclophosphamide prior to each trial.
Cyclophosphamide was detected in low concentrations
on the BSC workbench surfaces but not on the airfoil/
grill or ﬂoor following both trials.
It was postulated that vial contamination may con-
tribute to levels of cyclophosphamide on the work area
surfaces following the product trials. To determine if vial
contamination could have contributed to surface levels,
wipe samples were collected from the vials and the tech-
nician’s gloves. To help minimize possible vial contami-
nation from contributing to surface levels, vials were
placed on protective pads on either side of the demar-
cated area of the BSC workbench and the technician was
careful not to touch or place vials on the workbench.
Although many of the vials used in the study
had no detectable cyclophosphamide contamination,
the results showed that some vials used for the
ChemoCLAVE trial had detectable levels. The presence
of the chemical on the vials may have contributed to the
low level detected on the BSC workbench. It was
observed that on two occasions during the
ChemoCLAVE trial, a vial was inadvertently placed on
the BSC workbench by the technician performing the
simulated compounding duties. The presence of contam-
ination on some vials and on the technician’s gloves sug-
gests that the chemical was transferred to the gloves. It is
possiblethatcontaminationwasspreadtotheworkbench
by contact with syringes and/or IV bags that were han-
dled by the technician’s gloves. It is assumed that vial
contamination was reduced due to vial wipe sampling,
Table 2. Summary of pre-trial sample results
Prior to ChemoCLAVE
TM trial Prior to PhaSeal trial
Surface
description
Surface
area (cm
2)
Cyclophosphamide
(ng)
Cyclophosphamide
concentration (ng/cm
2)
Cyclophosphamide
(ng)
Cyclophosphamide
concentration (ng/cm
2)
Floor 4400 nd
a <0.004 nd <0.004
Airfoil/grill 2000 nd <0.008 nd <0.008
Workbench 4400 nd <0.004 nd <0.004
and ¼ not detected (cyclophosphamide<15.7ng).
Table 3. Summary of post-trial sample results
Following ChemoCLAVE
TM trial Following PhaSeal trial
Surface
description
Surface
area (cm
2)
Cyclophosphamide
(ng)
Cyclophosphamide
concentration (ng/cm
2)
Cyclophosphamide
(ng)
Cyclophosphamide
concentration (ng/cm
2)
Floor 4400 nd
a <0.004 nd <0.004
Airfoil/grill 2000 nd <0.008 nd <0.008
Workbench 4400 468 0.11 622 0.14
Gloves 2 gloves 377 na
b nd na
and ¼ not detected (cyclophosphamide<15.7ng).
bna ¼ not applicable.
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technician’s gloves and on surfaces if the vial wipe sam-
pling had not been conducted.
The surface transfer of the chemical as postulated
above with the ChemoCLAVE trial is an unlikely
factor in the PhaSeal trial. This is because, although
there was a low level of cyclophosphamide detected on
the BSC workbench following the PhaSeal trial, no con-
tamination was detected on the vials or on the pharmacy
technician’s gloves. It is possible that work practices and
procedures regarding product operation could have con-
tributed to surface contamination during the PhaSeal
trial. On two occurrences the Injector Luer Lock protec-
tive needle caps were not retracted when withdrawn
from the drug vials exposing the needle. Small droplets
that normally would otherwise be contained could have
possibly reached the BSC workbench. These occurrences
also posed needlestick hazards.
The concentrations reported in these results were
calculated with no determination of analyte recoveries
and wipe eﬃciencies. Therefore, all results reported are
estimates of the concentrations present on the surfaces
sampled.
Vial contamination may have contributed to the low
level of cyclophosphamide observed on the BSC work-
bench following the ChemoCLAVE trial. Work prac-
tices and procedures regarding product operation may
have contributed to the low level of cyclophosphamide
observed on the BSC workbench following the PhaSeal
trial. Work practices and procedures regarding product
operation appeared to be an important factor in haz-
ardous drug containment and needle safety when using
PhaSeal, but not when using ChemoCLAVE, which
requires fewer user steps and it is needle free. The
PhaSeal Injector Luer Lock model (REF N31) that
was used for this study has been replaced by a more
recent model (REF N35).
Based on the limited number of samples obtained
during this preliminary study and the determination
of the presence of the chemical of interest on the drug
vials, no statistical evaluation was performed to com-
pare the relative eﬀectiveness of the two systems tested.
Further study and statistical analyses are needed to
investigate the containment eﬀectiveness of the prod-
ucts in a controlled setting.
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